

(The body of the CRMP may be preceded by a description of the Change History, along with a Table of Contents, a List of Tables, a List of Figures, and a List of Abbreviations, as necessary.)

Table of Contents

LIST OF ABBREVIATIONS	4
1. PRODUCT OVERVIEW.....	5
2. SAFETY OVERVIEW	5
2.1. Summary of Safety Concerns	5
2.2. Epidemiology of the Indication(s).....	5
2.3. Important Identified Risks	6
2.4. Important Potential Risks.....	7
2.5. Important Missing Information	7
3. PHARMACOVIGILANCE PLAN	8
3.1. Routine Pharmacovigilance Activities	8
3.2. Additional Pharmacovigilance Activities	8
3.2.1. Planned/ Ongoing additional pharmacovigilance activities.....	9
3.2.2. Completed/terminated additional pharmacovigilance activities.....	9
4. PLANS FOR POST-AUTHORIZATION EFFICACY STUDIES.....	9
5. RISK MINIMIZATION MEASURES.....	10
5.1. Routine Risk Minimization Measures	10
5.2. Additional Risk Minimization Measures.....	10
6. REFERENCES.....	11
7. ANNEXES.....	11
7.1. Study Protocol(s) for Post-authorization Study/ies (if applicable)	11
7.2. Risk Minimization Plan (if applicable).....	11
7.3. Tools Used for Risk Minimization Measures (if applicable).....	11